Enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor
disease diseaseOn this page
Also known as carcinoid neoplasm of pancreascarcinoid neoplasm of the pancreascarcinoid tumor of pancreascarcinoid tumor of the pancreascarcinoid tumour of pancreascarcinoid tumour of the pancreasEC cell, serotonin producing pancreatic NETEC cell, serotonin producing pancreatic neuroendocrine tumorEC cell, serotonin producing pancreatic neuroendocrine tumourpancreatic carcinoid tumorpancreatic carcinoid tumourpancreatic serotonin producing neoplasmpancreatic serotonin producing tumorpancreatic serotonin producing tumourserotonin-producing neuroendocrine tumour of pancreasserotonin-producing pancreatic NETserotonin-producing pancreatic neuroendocrine tumorserotonin-producing pancreatic neuroendocrine tumourserotonin-producing PNET
Summary
Enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor (MONDO:0024504) is a cancer and 3 clinical trials. Top therapeutic interventions include paltusotine. A subtype of pancreatic neuroendocrine tumor G1 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor |
| Mondo ID | MONDO:0024504 |
| Orphanet | 506090 |
| NCIT | C4446 |
| UMLS | C0345933 |
| MedGen | 91057 |
| GARD | 0022055 |
| Is cancer (heuristic) | yes |
Also known as: carcinoid neoplasm of pancreas · carcinoid neoplasm of the pancreas · carcinoid tumor of pancreas · carcinoid tumor of the pancreas · carcinoid tumour of pancreas · carcinoid tumour of the pancreas · EC cell, serotonin producing pancreatic NET · EC cell, serotonin producing pancreatic neuroendocrine tumor · EC cell, serotonin producing pancreatic neuroendocrine tumour · enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor · pancreatic carcinoid tumor · pancreatic carcinoid tumour · pancreatic serotonin producing neoplasm · pancreatic serotonin producing tumor · pancreatic serotonin producing tumour · serotonin-producing neuroendocrine tumour of pancreas · serotonin-producing pancreatic NET · serotonin-producing pancreatic neuroendocrine tumor · serotonin-producing pancreatic neuroendocrine tumour · serotonin-producing PNET (+4 more)
Disease family
This is a subtype of pancreatic neuroendocrine tumor G1. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › neuroendocrine neoplasm › carcinoid tumor › pancreatic neuroendocrine tumor G1 › enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07087054 | PHASE3 | RECRUITING | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen |
| NCT05361668 | PHASE2 | COMPLETED | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome |
| NCT04907643 | Not specified | RECRUITING | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PALTUSOTINE | 3 | 2 |
Related Atlas pages
- Drugs: Paltusotine